File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Rise and fall of anti-obesity drugs

TitleRise and fall of anti-obesity drugs
Authors
KeywordsObesity
Anti-obesity drugs
Sibutramine
Rimonabant
Orlistat
Issue Date2011
PublisherBaishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/1948-9358/index.htm
Citation
World Journal of Diabetes, 2011, v. 2 n. 2, p. 19-23 How to Cite?
AbstractAlthough it is not generally a life-threatening disease, obesity is becoming a major health problem worldwide. It can be controlled by means of drugs, and, consequently, these are required to be safe as well as effective. In this paper, we summarize the fate of various drugs that have been introduced for clinical use in the treatment of obesity. Fenfluramine and dexfenfluramine were withdrawn because of heart valve damage. Sibutramine suppresses appetite and increases heart rate and blood pressure. In the Sibutramine Cardiovascular OUTcomes trial, an increase in major adverse cardiovascular events prompted its withdrawal in Europe and the United States. Rimonabant is an endocannabinoid receptor antagonist that reduces body weight and ameliorates some cardiovascular risk factors. However, adverse psychiatric side effects led to its withdrawal as well. Orlistat is approved in Europe and the United States for the treatment of obesity, but its use is limited by gastrointestinal side-effects. Ephedrine and caffeine are natural ingredients in foods and supplements that may help the person to lose weight. In the light of several failed attempts, there is a clear need to develop drugs that are effective and safe in the long term in order to successfully combat the phenomenon of obesity .
Persistent Identifierhttp://hdl.handle.net/10722/129279
ISSN
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorLi, MFen_US
dc.contributor.authorCheung, BMYen_US
dc.date.accessioned2010-12-23T08:34:38Z-
dc.date.available2010-12-23T08:34:38Z-
dc.date.issued2011en_US
dc.identifier.citationWorld Journal of Diabetes, 2011, v. 2 n. 2, p. 19-23en_US
dc.identifier.issn1948-9358-
dc.identifier.urihttp://hdl.handle.net/10722/129279-
dc.description.abstractAlthough it is not generally a life-threatening disease, obesity is becoming a major health problem worldwide. It can be controlled by means of drugs, and, consequently, these are required to be safe as well as effective. In this paper, we summarize the fate of various drugs that have been introduced for clinical use in the treatment of obesity. Fenfluramine and dexfenfluramine were withdrawn because of heart valve damage. Sibutramine suppresses appetite and increases heart rate and blood pressure. In the Sibutramine Cardiovascular OUTcomes trial, an increase in major adverse cardiovascular events prompted its withdrawal in Europe and the United States. Rimonabant is an endocannabinoid receptor antagonist that reduces body weight and ameliorates some cardiovascular risk factors. However, adverse psychiatric side effects led to its withdrawal as well. Orlistat is approved in Europe and the United States for the treatment of obesity, but its use is limited by gastrointestinal side-effects. Ephedrine and caffeine are natural ingredients in foods and supplements that may help the person to lose weight. In the light of several failed attempts, there is a clear need to develop drugs that are effective and safe in the long term in order to successfully combat the phenomenon of obesity .-
dc.languageengen_US
dc.publisherBaishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/1948-9358/index.htm-
dc.relation.ispartofWorld Journal of Diabetesen_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectObesity-
dc.subjectAnti-obesity drugs-
dc.subjectSibutramine-
dc.subjectRimonabant-
dc.subjectOrlistat-
dc.titleRise and fall of anti-obesity drugsen_US
dc.typeArticleen_US
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1948-9358&volume=2&issue=2&spage=19&epage=23&date=2011&atitle=Rise+and+fall+of+anti-obesity+drugs-
dc.identifier.emailCheung, BMY: mycheung@hku.hken_US
dc.identifier.authorityCheung, BMY=rp01321en_US
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.4239/wjd.v2.i2.19-
dc.identifier.pmid21537456-
dc.identifier.pmcidPMC3083904-
dc.identifier.hkuros183467en_US
dc.identifier.hkuros187091-
dc.identifier.volume2-
dc.identifier.issue2-
dc.identifier.spage19-
dc.identifier.epage23-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats